Dorval Allison sold $84K of PBYI
Dorval Allison sold 11,610 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 on 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider sales can influence sentiment, but 10b5-1 plans typically reduce interpretability as a signal about near-term fundamentals.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure lacks new fundamental information.
What to watch
The filing does not state motivations, and the post-transaction holdings (90,780 shares) suggest the director did not exit the position.
Background
The article is a SEC Form 4 insider transaction filing for PUMA Biotechnology, Inc. (PBYI) by director Dorval Allison.
Ticker impact
Dorval Allison, a PBYI director, sold 11,610 shares in an open-market transaction at $7.1989 on 2026-06-12 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be small and short-lived unless followed by additional disclosures.
Form 4 provides transaction details (size, price, 10b5-1), but the article does not include new company guidance, results, regulatory actions, or deal news.
Market effects
No sector-level implications disclosed; this is company-specific insider transaction reporting.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerPUMA BIOTECHNOLOGY, INC.
Company whose director insider sale is disclosed via SEC Form 4.
- insiderDorval Allison
Director who sold 11,610 shares under a Rule 10b5-1 plan.
